Opinion|Videos|March 22, 2024

Bladder Cancer: Treatment in the Metastatic Setting

Author(s)Rahul Gosain, MD, Rohit Gosain, MD, Karine Tawagi, MD

Focusing on the metastatic setting, the expert panel discusses advanced kidney cancer treatment practices, highlighting recent data that are informing treatment decisions.

Episodes in this series

Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides

EP. 1 Treatment Algorithm for Non–Muscle-Invasive Bladder Cancer (NMIBC)

Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides

EP. 2 Muscle-Invasive Bladder Cancer Treatment Practices

Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides

EP. 3 Bladder Cancer: Treatment in the Metastatic Setting

Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides

EP. 4 Recap: Bladder Cancer Treatment Algorithm

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

Human Body Organs (Urinary Bladder) | Image Credit: © magicmine - stock.adobe.com.

September 25th, 2026

Durvalumab Plus Enfortumab Vedotin Earns FDA Priority Review in MIBC

The FDA granted priority review to perioperative durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive disease, based on phase 3 VOLGA data.

Trending on CancerNetwork

What Does TALAPRO-3 Mean for Frontline Treatment of HRR-Altered mHSPC?

Aglatimagene Combo Shows Sustained Immune Remodeling in Prostate Cancer

CARTITUDE-2 Cohort A Follow-Up Data and Preparing Patients for CAR TCell Therapy

Ciltacabtagene Autoleucel Manufacturing, Debulking, and Bridging in Multiple Myeloma

Referral Barriers to Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma